`
`Complete ifKnown
`
`Ecuivalent of Form PTO/SB/O8b 7-09)
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`
`(Use as many sheets as necessary)
`
`Alexander OKSCHE
`
`RICCL Craig D.
`1861.2700006/JMC/MSB
`
`
`
`
`
`Examiner
`Initials*
`
`NON PATENT LITERATURE DOCUMENTS
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when
`appropriate), title of the item (book, magazine, journal, serial, symposium, catalog,
`etc.), date, page(s), volume-issue number(s), publisher, city and/or country where
`published
`
`HELM II, S., et al., “Opioid Antagonists, Partial Agonists, and Agonists/Antagonists:
`The Role of Office-Based Detoxif1caion,” Pain Physician 11:225-235, American
`Society of Interventional Pain Physicians, United States (2008)
`
`HOSKIN, PJ., et al., “Opioid agonist-antagonist drugs in acute and chronic pain
`states,” Drugs 14:326-344,Review Article (1991)
`
`HUNG, C.F., et al., “The Differential Effects of a Selective Kappa-Opioid Receptor
`Agonist, U50488, in Guinea Pig Heart Tissues,” Research Article, 6 pages, Hindawi
`Publishing Corporation (2015)
`
`LUTFY, K., et al., “Buprenorphine: A Unique Drug with Complex Pharmacology,”
`Curr Neuropharmacol. 22395-402, Bentham Science, United Arab (2004)
`
`NAKAO, K., et al., “Nalfurafine hydrochloride, a selective K opioid receptor agonist,
`has no reinforcing effect on intravenous self-administration in rhesus monkeys,”
`Journal of Pharmacological Sciences 13028-14, Elsevier, Netherlands (2016)
`
`PARONIS, C., et al., “Buprenorphine and Opioid Antagonism, Tolerance, and
`Naltrexone-Precipitated Withdrawal,” The Journal of Pharmacology and
`Experimental Therapeutics 3 36 :488- 1 95, ASPET, United States(2010)
`
`Petition for INTER PARTES REVIEW INDIVIOR INC. v. RHODES
`
`PHARMACEUTICALS L.P., US. Patent no. 9,370,512, March 16, 2018, 78 pages
`
`9169221_l.d0cx
`
`Examiner
`
`Signature
`
`Date
`
`Considered
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance
`and not considered. Include copy of this form with next communication to applicant.
`1 Applicant’s unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
